Although GLP-1 agonists are generally prescribed to promote weight loss, this finding may reflect clinical prescribing patterns in which providers are more likely to initiate these medications in patients with more severe obesity, leading to a higher average BMI among users. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.